Warning: Illegal string offset 'name' in /homepages/29/d231077926/htdocs/review/wp-content/plugins/genesis-simple-sidebars/plugin.php on line 105

Warning: Illegal string offset 'description' in /homepages/29/d231077926/htdocs/review/wp-content/plugins/genesis-simple-sidebars/plugin.php on line 107
Augmenix - Company — Augmenix


Augmenix Vision

Augmenix was founded to develop hydrogel technology to improve outcomes in radiation oncology and surgery. The company is using this technology to develop products that decrease unintended radiation damage to normal organs during radiation therapy and to mark soft tissue.

Despite recent improvements in in radiation delivery, the need to reliably target cancerous tissues while minimizing injury to healthily structures remains central to safe and effective radiotherapy. The challenge of nearby healthy tissues often force the clinician into a compromise – deliver enough radiation to kill the cancer, or reduce the radiation to have acceptable side effects.  To answer this challenge in prostate radiotherapy, Augmenix developed the SpaceOAR® System, an absorbable hydrogel that temporarily moves the rectum away from the prostate and the high intensity radiation zone. This extra space should both reduce rectal complications and allow the clinician to focus on their main objective – killing the cancer.

More recently Augmenix has developed an absorbable tissue marker that marks soft tissue for a surgical procedure or future surgical procedures. TraceIT Tissue Marker is visible on multi-modality imaging allowing for improved tissue marking.

This technology licensed from Incept LLC comes from a line of products that have made a meaningful impact in the areas of neurosurgery and interventional cardiology. Augmenix now intends to bring this technology to the field of medicine through an experienced management team and high quality investors.

TraceIT Tissue MarkerSpaceOAR System